Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chi Sheng Pharma & Biotech CoROCO:4111 -0.67%84 5-Year Yield-on-Cost % is 3.56 as of Aug. 14, 2026, which is at its 10-year median of 3.56. GuruFocus rates ROCO:4111 with a GF Score™ of 84/100 and a GF Value™ of NT$33.61 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 316 Medical Devices & Instruments companies, Chi Sheng Pharma & Biotech Co ranks better than 64.56% on this metric.
The historical rank and industry rank for Chi Sheng Pharma & Biotech Co's 5-Year Yield-on-Cost % or its related term are showing as below:
ROCO:4111'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.8 Med: 3.56 Max: 5.19
Current: 3.56
During the past 13 years, Chi Sheng Pharma & Biotech Co's highest Yield on Cost was 5.19. The lowest was 1.80. And the median was 3.56.
ROCO:4111's 5-Year Yield-on-Cost % is ranked better than 64.56% of 316
companies
in the Medical Devices & Instruments industry
Industry Median: 2.36
vs ROCO:4111: 3.56
Chi Sheng Pharma & Biotech Co (ROCO:4111) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Chi Sheng Pharma & Biotech Co 5-Year Yield-on-Cost % Related Terms
ROCO:4111 vs ISRG, BDX, MDLN: 5-Year Yield-on-Cost % Comparison
For the Medical Instruments & Supplies subindustry, Chi Sheng Pharma & Biotech Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chi Sheng Pharma & Biotech Co 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Chi Sheng Pharma & Biotech Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Chi Sheng Pharma & Biotech Co's 5-Year Yield-on-Cost % falls into.
Chi Sheng Pharma & Biotech Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Chi Sheng Pharma & Biotech Co (ROCO:4111) has a 5-Year Yield-on-Cost % of 3.56 as of Aug. 14, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Chi Sheng Pharma & Biotech Co and its competitors. This is near median its historical median of 3.56. Over the past decade, Chi Sheng Pharma & Biotech Co's 5-Year Yield-on-Cost % has ranged from 1.80 to 5.19. According to the industry distribution chart, Chi Sheng Pharma & Biotech Co ranks #112 out of 316 companies in the Medical Devices & Instruments industry, placing it in the top 35.4%.
Is Chi Sheng Pharma & Biotech Co's 5-Year Yield-on-Cost % too high?
Chi Sheng Pharma & Biotech Co's current 5-Year Yield-on-Cost % of 3.56 is near median its 10-year median of 3.56. Over the past 10 years, this metric has ranged from a low of 1.80 to a high of 5.19. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.36. Chi Sheng Pharma & Biotech Co's value of 3.56 is 50.8% above this industry median. Based on the distribution chart, Chi Sheng Pharma & Biotech Co ranks #112 out of 316 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Chi Sheng Pharma & Biotech Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chi Sheng Pharma & Biotech Co's 5-Year Yield-on-Cost % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Chi Sheng Pharma & Biotech Co ranks #112 out of 316 companies for 5-Year Yield-on-Cost %. This puts Chi Sheng Pharma & Biotech Co in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.36. Chi Sheng Pharma & Biotech Co's value of 3.56 is 50.8% above this benchmark. Historically, Chi Sheng Pharma & Biotech Co's own 5-Year Yield-on-Cost % has ranged from 1.80 to 5.19 over the past decade. While the company's 10-year median is 3.56 vs. the industry median of 2.36, Chi Sheng Pharma & Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.36, based on 316 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chi Sheng Pharma & Biotech Co's current 5-Year Yield-on-Cost % of 3.56 is 50.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Chi Sheng Pharma & Biotech Co and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chi Sheng Pharma & Biotech Co's current 5-Year Yield-on-Cost % is 3.56, which is near median its own 10-year median of 3.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chi Sheng Pharma & Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Chi Sheng Pharma & Biotech Co (ROCO:4111) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$33.61, compared to a current price of NT$29.85 — trading 11.2% below its estimated fair value. The current 5-Year Yield-on-Cost % is 3.56, which is near median its 10-year median of 3.56 and 50.8% above the Medical Devices & Instruments industry median of 2.36. Chi Sheng Pharma & Biotech Co's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Chi Sheng Pharma & Biotech Co (ROCO:4111), the current 5-Year Yield-on-Cost % is 3.56 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chi Sheng Pharma & Biotech Co (ROCO:4111) Overvalued in 2026?
Based on GuruFocus' analysis, Chi Sheng Pharma & Biotech Co stock appears to be undervalued.
The current stock price of NT$29.85 is trading 11.2% below its estimated GF Value™ of NT$33.61.
GuruFocus considers Chi Sheng Pharma & Biotech Co to be Modestly Undervalued.
Key valuation signals for ROCO:4111:
5-Year Yield-on-Cost %: 3.56 (near median its 10-year median of 3.56)
GF Value™: NT$33.61 vs. price of NT$29.85 (11.2% below fair value)
Industry Position: 50.8% above the Medical Devices & Instruments median (#112 of 316)
No single metric tells the full story. See the ROCO:4111 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chi Sheng Pharma & Biotech Co Ltd manufactures and distributes medical medicines and equipment in Taiwan. It offers injections, including hemodialysis solutions, amino acid injections, vitamin injections, and externally applied medicines.
84GF Score
Get the complete analysis for ROCO:4111
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4111 has been successfully added to your 
